Eli Lilly and Company $LLY Holdings Raised by Flputnam Investment Management Co.

Flputnam Investment Management Co. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 4.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 56,285 shares of the company’s stock after purchasing an additional 2,471 shares during the quarter. Eli Lilly and Company comprises about 0.9% of Flputnam Investment Management Co.’s investment portfolio, making the stock its 22nd largest holding. Flputnam Investment Management Co.’s holdings in Eli Lilly and Company were worth $60,488,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. M3 Wealth Management LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $1,590,000. Goodwin Investment Advisory bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $268,000. Poinciana Advisors Group LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $217,000. Integrity Alliance LLC. raised its stake in shares of Eli Lilly and Company by 93.7% during the fourth quarter. Integrity Alliance LLC. now owns 8,290 shares of the company’s stock valued at $8,910,000 after purchasing an additional 4,011 shares in the last quarter. Finally, Bellwether Advisors LLC bought a new stake in shares of Eli Lilly and Company during the fourth quarter valued at about $2,289,000. 82.53% of the stock is currently owned by institutional investors.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly announced it will acquire three vaccine developers — Curevo, LimmaTech Biologics, and Vaccine Company — in deals worth up to about $3.8 billion, expanding its infectious-disease and vaccine portfolio beyond diabetes and obesity. Lilly announces three acquisitions to build infectious disease portfolio
• Positive Sentiment: Investors also reacted to strong news from Lilly’s experimental gene therapy VERVE-102, which cut LDL cholesterol and PCSK9 sharply in early trial data, reinforcing optimism around the company’s broader growth pipeline. VERVE-102 trial results
• Positive Sentiment: Analysts and media coverage continued to highlight Lilly as a long-term winner in obesity and pharma, supported by persistent demand for its weight-loss drugs and upbeat commentary on its growth prospects. Motley Fool article on undervaluation
• Neutral Sentiment: Broader market gains and hopes for a diplomatic resolution between the U.S. and Iran helped lift equities overall, providing a supportive backdrop for Lilly alongside the company-specific headlines. Market wrap article
• Neutral Sentiment: Some healthcare-sector weakness on the day may have partially offset the company-specific optimism, but it does not appear to be the main driver for LLY. Healthcare sector decline article

Analyst Ratings Changes

LLY has been the topic of a number of recent analyst reports. Scotiabank restated an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Guggenheim restated a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, May 5th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Morgan Stanley restated an “overweight” rating and set a $1,344.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 1st. Finally, Wells Fargo & Company lifted their target price on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,227.00.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $1,066.77 on Wednesday. The business’s 50-day moving average price is $946.28 and its 200 day moving average price is $1,006.64. The firm has a market cap of $1.00 trillion, a P/E ratio of 37.90, a PEG ratio of 1.16 and a beta of 0.48. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion for the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.Eli Lilly and Company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 35.82 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s payout ratio is presently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.